Ann: First Kidney Transplant Trial Patient Treated, page-2

Can't beat iPSC's.

Dr Spijker said:
“One of the most useful properties of MSCs is that they can instruct the immune system to slow down,
and tell it not to attack the new kidney as aggressively. This could allow patients to take less rejection
medication to preserve the kidney, or potentially even stop taking rejection medication completely. Our
previous studies involved MSCs derived from bone marrow, which is quite a tedious procedure, and one
that produces just a limited amount of MSCs. In contrast, Cynata’s iPSC-based platform allows
production of an effectively limitless supply of MSCs from one cell bank. We look forward to evaluating
these cells in this exciting study.”